Clinical Trial Update: A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating eltrombopag, a thrombopoietin-receptor agonist, in patients with low- to intermediate-2 risk myelodysplastic syndromes and thromb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Myelodysplastic Syndromes, Thrombocytopenia | Phase 2 | Status: COMPLETED | Results posted: 2019-08-22